This study is, to our knowledge, the largest complete cohort collection of safety and outcome information on the first approved ocular gene therapy in patients with biallelic RPE65 mutation-associated IRDs in a clinical setting. This evidence concerns the gene RPE65 and respiratory distress syndrome in premature infants.